Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage IV EGFR Mutated Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01922583
What this trial is testing

AUY922 in Patient With Stage IV NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
National Taiwan University Hospital 31
Testing effectiveness (Phase 2)UnknownNCT03647956
What this trial is testing

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Activating Mutation
The University of Hong Kong 40
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Testing effectiveness (Phase 2)Ended earlyNCT02949843
What this trial is testing

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Who this might be right for
EGFR Activating MutationRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences 19
Not applicableUnknownNCT04768491
What this trial is testing

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Activating MutationNSCLC Stage IVNSCLC Stage IIIB+1 more
Peking Union Medical College 82
Testing effectiveness (Phase 2)Study completedNCT01532089
What this trial is testing

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
EGFR Exon 19 Deletion MutationEGFR NP_005219.2:p.L858RLung Non-Squamous Non-Small Cell Carcinoma+1 more
Academic and Community Cancer Research United 88
Testing effectiveness (Phase 2)Ended earlyNCT03805841
What this trial is testing

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Who this might be right for
NSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIIC+5 more
Rain Oncology Inc 41
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Ended earlyNCT02846792
What this trial is testing

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Who this might be right for
ALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more
University of Washington 5
Testing effectiveness (Phase 2)Ended earlyNCT03066206
What this trial is testing

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Who this might be right for
EGFR Exon 20 MutationERBB2 Gene MutationRecurrent Lung Non-Small Cell Carcinoma+1 more
M.D. Anderson Cancer Center 93
Testing effectiveness (Phase 2)Study completedNCT04764214
What this trial is testing

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Who this might be right for
NSCLC Stage IVEGFR Activating Mutation
Fudan University 61
Early research (Phase 1)Study completedNCT01998126
What this trial is testing

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
University of Utah 14
Not applicableStudy completedNCT01081496
What this trial is testing

Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 1,000
Post-approval studies (Phase 4)UnknownNCT01646450
What this trial is testing

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 35
Not applicableActive Not RecruitingNCT06538038
What this trial is testing

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerEpidermal Growth Factor Receptor Gene MutationStage III Lung Cancer+1 more
PrECOG, LLC. 200
Large-scale testing (Phase 3)UnknownNCT03991403
What this trial is testing

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Samsung Medical Center 228
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Large-scale testing (Phase 3)UnknownNCT02001896
What this trial is testing

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Xinjiang Medical University 60
Early research (Phase 1)Active Not RecruitingNCT02503722
What this trial is testing

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7+3 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07298148
What this trial is testing

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

Who this might be right for
NSCLC Stage IVEGFR Positive Non-small Cell Lung CancerEGFR-TKI Sensitizing Mutation
Peking University Cancer Hospital & Institute 28
Next Page